Transcode Therapeutics (RNAZ) Net Cash Flow (2020 - 2026)

Transcode Therapeutics (RNAZ) has reported Net Cash Flow for 7 consecutive years, with -$5.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 28.74% year-over-year to -$5.4 million; the trailing twelve-month figure through Jun 2026 stood at $43142.0 (down 98.93% YoY), and the FY2025 full-year result was $12.0 million, up 294.37% from the prior year.
• Net Cash Flow eased to -$5.4 million in Q2 2026 per RNAZ's latest filing, from -$5.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $15.0 million in Q4 2025 and bottomed at -$5.4 million in Q2 2026.
• Historically, Net Cash Flow has averaged -$744883.5 across 5 years, with a median of -$3.4 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow sank 17503.72% in 2022, then surged 281.37% in 2025.
• Over 5 years, Net Cash Flow stood at -$3.8 million in 2022, then fell by 22.58% to -$4.7 million in 2023, then surged by 183.99% to $3.9 million in 2024, then soared by 281.37% to $15.0 million in 2025, then slumped by 135.98% to -$5.4 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$5.4 million, -$5.0 million, and $15.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.